Subscribe to our Newsletters !!
Like never seen before, coral reefs across the
Labs today face mounting pressure to cut carbon em
Dr. Mohammed Enayat’s recent testimony on his ag
It is with utmost pride that Microbioz India annou
30th June, 2025 Mumbai: Alembic Pharmaceuticals Li
Since it’s an ingredient in so many foods, you h
In our cover story, we shine a spotlight on “ The Magazine
Effective antivirals with secure clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients using COVID-19, the authors discovered that hypercoagulability according to elevated levels of D-dimers was associated with illness severity.
By calculating of a U.S. FDA approved drug library, the authors identified that an anticoagulation agent dipyridamole (DIP) at silico, which suppressed SARS-CoV-2 replication invitro.
At a proof-of-concept trial between 31 patients using COVID-19, DIP supplementation has been associated with significantly decreased concentrations of D-dimers (P<0.05), greater lymphocyte and platelet recovery in the flow, and markedly enhanced clinical outcomes for the severely ill patients compared with the control patients.
To sum up, DIP could be used for the treatment of seriously ill patients using COVID-19 through antibacterial and anticoagulation consequences.
Ascension Parish School Board
Liu, X., et al. (2020) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Elsevier. doi.org/10.1016/j.apsb.2020.04.008.
